The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma
Open accessAbstract
Epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and human epidermal growth factor receptor 2 (HER2) have been considered as potential therapeutic targets in cholangiocarcinoma, but no studies have yet clarified the clinicopathological or prognostic significance of these molecules. Immunohistochemical expression of these molecules was assessed retrospectively in 236 cases of cholangiocarcinoma, as well as associations between the expression of these molecules and clinicopathological factors or clinical outcome. The proportions of positive cases for EGFR, VEGF, and HER2 overexpression were 27.4, 53.8, and 0.9% in intrahepatic cholangiocarcinoma (IHCC), and 19.2, 59.2, and 8.5% in extrahepatic cholangiocarcinoma (EHCC), respectively. Clinicopathologically, EGFR overexpression was associated with macroscopic type (P=0.0120), lymph node metastasis (P=0.0006), tumour stage (P=0.0424), lymphatic vessel invasion (P=0.0371), and perineural invasion (P=0.0459) in EHCC, and VEGF overexpression with intrahepatic metastasis (P=0.0224) in IHCC. Multivariate analysis showed that EGFR expression was a significant prognostic factor (hazard ratio (HR), 2.67; 95% confidence interval (CI), 1.52-4.69; P=0.0006) and also a risk factor for tumour recurrence (HR, 1.89; 95% CI, 1.05-3.39, P=0.0335) in IHCC. These results suggest that EGFR expression is associated with tumour progression and VEGF expression may be involved in haematogenic metastasis in cholangiocarcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TNM Classification of Malignant Tumours
(1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,049
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · cited 2×
“…such as epidermal growth factor and transforming growth factor alpha (TGFa), to their extracellular ligand-binding domain initiates intracellular signalling cascades, leading to progression, proliferation, migration, and survival of cancer cells (Olayioye et al, 2000; Yarden and Sliwkowski, 2001).”
BackgroundPaclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma
Weidner, N., Semple, J. P., Welch, W. R., & Folkman, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101033240101 · Cited by 5,627
TNM Classification of Malignant Tumours
(2003) · John Wiley & Sons, Inc. eBooks · doi:10.1002/0471463752 · Cited by 3,946
Olayioye, M. A. (2000) · The EMBO Journal · doi:10.1093/emboj/19.13.3159 · Cited by 2,434
Nicholson, R. I., Gee, J. M. W., & Harper, M. E. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00231-3 · Cited by 2,143
Resected adenocarcinoma of the pancreas—616 patients: results, outcomes, and prognostic indicators
Sohn, T. A., Yeo, C. J., Cameron, J. L., Koniaris, L., Kaushal, S., Abrams, R. A., Sauter, P. K., Coleman, J., Hruban, R. H., & Lillemoe, K. D. (2000) · Journal of Gastrointestinal Surgery · doi:10.1016/s1091-255x(00)80105-5 · Cited by 1,485
Cholangiocarcinoma: Thirty-one-Year Experience With 564 Patients at a Single Institution
DeOliveira, M. L., Cunningham, S. C., Cameron, J. L., Kamangar, F., Winter, J. M., Lillemoe, K. D., Choti, M. A., Yeo, C. J., & Schulick, R. D. (2007) · Annals of Surgery · doi:10.1097/01.sla.0000251366.62632.d3 · Cited by 1,300
Cholangiocarcinoma: A Spectrum of Intrahepatic, Perihilar, and Distal Tumors
Nakeeb, A., Pitt, H. A., Sohn, T. A., Coleman, J., Abrams, R. A., Piantadosi, S., Hruban, R. H., Lillemoe, K. D., Yeo, C. J., & Cameron, J. L. (1996) · Annals of Surgery · doi:10.1097/00000658-199610000-00005 · Cited by 1,187
Khan, S. A., Thomas, H. C., Davidson, B. R., & Taylor-Robinson, S. D. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67530-7 · Cited by 1,042
Angiogenesis and Tumor Metastasis
Zetter, B. R. (1998) · Annual Review of Medicine · doi:10.1146/annurev.med.49.1.407 · Cited by 1,015
Gusterson, B. A., Gelber, R. D., Goldhirsch, A., Price, K. N., Säve-Söderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C. M., Golouh, R., & Reed, R. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1049 · Cited by 838
Clark, A. N. G., Mankikar, G. D., & Gray, I. (1975) · The Lancet · doi:10.1016/s0140-6736(75)91280-5 · Cited by 697
Neal, D., Bennett, M., Hall, R., Marsh, C., Abel, P., Sainsbury, J. R. C., & Harris, A. (1985) · The Lancet · doi:10.1016/s0140-6736(85)91386-8 · Cited by 604
The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents
Tabernero, J. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0404 · Cited by 437
Des Guetz, G., Uzzan, B., Nicolas, P., Cucherat, M., Morere, J.-F., Benamouzig, R., Breau, J.-L., & Perret, G.-Y. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603176 · Cited by 406
Phase II Study of Erlotinib in Patients With Advanced Biliary Cancer
Philip, P. A., Mahoney, M. R., Allmer, C., Thomas, J., Pitot, H. C., Kim, G., Donehower, R. C., Fitch, T., Picus, J., & Erlichman, C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3579 · Cited by 318
Cholangiocarcinoma: Molecular targeting strategies for chemoprevention and therapy
Sirica, A. E. (2005) · Hepatology · doi:10.1002/hep.20537 · Cited by 315
Shaib, Y. H., El-Serag, H. B., Nooka, A. K., Thomas, M., Brown, T. D., Patt, Y. Z., & Hassan, M. M. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01104.x · Cited by 258
Nakazawa, K., Dobashi, Y., Suzuki, S., Fujii, H., Takeda, Y., & Ooi, A. (2005) · The Journal of Pathology · doi:10.1002/path.1779 · Cited by 234
Han, H., Silverman, J. F., Santucci, T. S., Macherey, R. S., dAmato, T. A., Tung, M. Y., Weyant, R. J., & Landreneau, R. J. (2001) · Annals of Surgical Oncology · doi:10.1007/s10434-001-0072-y · Cited by 213
Histologic Risk Factors and Clinical Outcome in Colorectal Malignant Polyp: A Pooled-Data Analysis
Hassan, C., Zullo, A., Risio, M., Rossini, F. P., & Morini, S. (2005) · Diseases of the Colon & Rectum · doi:10.1007/s10350-005-0063-3 · Cited by 206
Endo, K., Yoon, B.-I., Pairojkul, C., Demetris, A. J., & Sirica, A. E. (2002) · Hepatology · doi:10.1053/jhep.2002.34435 · Cited by 188
Somatic Mutations of Epidermal Growth Factor Receptor in Bile Duct and Gallbladder Carcinoma
Leone, F., Cavalloni, G., Pignochino, Y., Sarotto, I., Ferraris, R., Piacibello, W., Venesio, T., Capussotti, L., Risio, M., & Aglietta, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1692 · Cited by 170
Development and differentiation of bile ducts in the mammalian liver
Shiojiri, N. (1997) · Microscopy Research and Technique · doi:10.1002/(sici)1097-0029(19971115)39:4<328::aid-jemt3>3.0.co;2-d · Cited by 141
Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells
Yoon, J., Gwak, G., Lee, H.-S., Bronk, S. F., Werneburg, N. W., & Gores, G. J. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.07.016 · Cited by 132
Aishima, S., Taguchi, K., Sugimachi, K., Shimada, M., Sugimachi, K., & Tsuneyoshi, M. (2002) · Histopathology · doi:10.1046/j.1365-2559.2002.00353.x · Cited by 119
Gwak, G., Yoon, J., Shin, C. M., Ahn, Y. J., Chung, J., Kim, Y. A., Kim, T., & Lee, H. S. (2005) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-005-0016-1 · Cited by 108
Adjuvant Therapy with Trastuzumab for HER-2/neu-Positive Breast Cancer
Gonzalez-Angulo, A. M., Hortobágyi, G. N., & Esteva, F. J. (2006) · The Oncologist · doi:10.1634/theoncologist.11-8-857 · Cited by 102
Tang, D., Nagano, H., Yamamoto, H., Wada, H., Nakamura, M., Kondo, M., Ôta, H., Yoshioka, S., Kato, H., Damdinsuren, B., et al. (2006) · Oncology Reports · doi:10.3892/or.15.3.525 · Cited by 88
Expression and Clinical Significance of the erbB Family in Intrahepatic Cholangiocellular Carcinoma
Ito, Y., Ito, Y., Takeda, T., Sasaki, Y., Sakon, M., Yamada, T., Ishiguro, S., Imaoka, S., Tsujimoto, M., Higashiyama, S., et al. (2001) · Pathology - Research and Practice · doi:10.1078/0344-0338-00016 · Cited by 80
Shirabe, K., Shimada, M., Tsujita, E., Aishima, S.-I., Maehara, S., Tanaka, S., Takenaka, K., & Maehara, Y. (2004) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2003.12.044 · Cited by 36
(2001) · PubMed
Cited by
Razumilava, N., & Gores, G. J. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61903-0 · Cited by 1,729
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
Bridgewater, J., Galle, P. R., Khan, S. A., Llovet, J. M., Park, J.-W., Patel, T., Pawlik, T. M., & Gores, G. J. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.021 · Cited by 1,511
Banales, J. M., Cardinale, V., Carpino, G., Marzioni, M., Andersen, J. B., Invernizzi, P., Lind, G. E., Folseraas, T., Forbes, S. J., Fouassier, L., et al. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.51 · Cited by 1,376
The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer
Affo, S., Yu, L.-X., & Schwabe, R. F. (2017) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100322 · Cited by 757
“In addition to inflammation, CCA is characterized by high expression of both VEGF (232) and VEGF receptors (233, 234).”
BackgroundNew Horizons for Precision Medicine in Biliary Tract Cancers
Valle, J. W., Lamarca, A., Goyal, L., Barriuso, J., & Zhu, A. X. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0245 · Cited by 626
Metadata
- Authors
- Yoshikawa, D., Ojima, H., Iwasaki, M., Hiraoka, N., Kosuge, T., Kasai, S., Hirohashi, S., & Shibata, T.
- Venue
- British Journal of Cancer
- Published
- 2007-12-18
- Volume
- 98
- Issue
- 2
- Pages
- 418-425
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2063515380
- Cited by
- 404
- References
- 35
- FWCI
- 10.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.